focus -WSS

focus

author：explore 2025-10-04 10:22:07 Page View：8

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： CDC panel: People 65 and older should get a Covid spring booster shot
Next article： Heart attack and stroke risk calculators need revising

explore

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

European officials brace for rough respiratory virus season

FinnbarrWebster/GettyImagesLONDON—HealthofficialsintheU.K.andEuropearerampinguptheircampaignsurginge

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Congress extends some pandemic preparedness programs

STEFANIREYNOLDS/AFPviaGettyImagesWASHINGTON—Congresstemporarilyextendedafewpandemic-preparednessprog

focus

leisure time

explore

Congress extends some pandemic preparedness programs